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OBJECTIVES The purpose of the study was to investigate the effects of beta1-blockade on left ventricular
(LV) size and function for patients with chronic heart failure.
BACKGROUND Large-scale trials have shown that a marked decrease in mortality can be obtained by
treatment of chronic heart failure with beta-adrenergic blocking agents. Possible mechanisms
behind this effect remain yet to be fully elucidated, and previous studies have presented
insignificant results regarding suspected LV antiremodeling effects.
METHODS In this randomized, placebo-controlled and double-blind substudy to the Metoprolol CR/XL
Randomized Intervention Trial in Heart Failure (MERIT-HF), 41 patients were examined
with magnetic resonance imaging three times in a six-month period, assessing LV dimensions
and function.
RESULTS Decreases in both LV end-diastolic volume index (150 ml/m2 at baseline to 126 ml/m2 after
six months, p 5 0.007) and LV end-systolic volume index (107 ml/m2 to 81 ml/m2, p 5
0.001) were found, whereas LV ejection fraction increased in the metoprolol CR/XL group
(29% to 37%, p 5 0.005). No significant changes were seen in the placebo group regarding
these variables. Left ventricular stroke volume index remained unchanged, whereas LV mass
index decreased in both groups (175 g/m2 to 160 g/m2 in the placebo group [p 5 0.005] and
179 g/m2 to 164 g/m2 in the metoprolol CR/XL group [p 5 0.01]).
CONCLUSIONS This study is the first randomized study to demonstrate that the beta1-blocker metoprolol
CR/XL has antiremodeling effects on the LV in patients with chronic heart failure and
consequently provides an explanation for the highly significant decrease in mortality from
worsening heart failure found in the MERIT-HF trial. (J Am Coll Cardiol 2000;36:
2072–80) © 2000 by the American College of Cardiology
Treatment of heart failure with beta-adrenergic blocking
agents has been intensely investigated during the past 20
years (1–9). Recently, it has been shown that a substantial
benefit on survival can be obtained by beta-blocker treat-
ment of patients with ischemic and nonischemic chronic
heart failure (10–13). The largest and most recently pub-
lished mortality trial is the Metoprolol CR/XL Randomized
Intervention Trial in Heart Failure study (MERIT-HF), in
which 3,991 patients with symptomatic heart failure in New
York Heart Association (NYHA) functional classes II to IV
were randomized to either placebo or metoprolol CR/XL
(controlled release/extended release), which is a beta1-
selective receptor antagonist with no intrinsic activity in a
slow release formulation. The beta-blocker was given in
addition to conventional heart failure treatment. In the
MERIT-HF trial, a reduction in total mortality of 34% in
the metoprolol CR/XL group compared with the placebo
group was found. However, the mechanism behind the
marked effect of beta-blocker treatment on survival in heart
failure is not yet fully understood (14–17). When examined
in detail, the data from the MERIT-HF trial revealed a
significant reduction in the number of deaths from worsen-
ing heart failure of 49% as well as a significant reduction in
mortality from sudden death of 40% (12,18). A number of
studies into the hemodynamic effects of chronic heart failure
treatment with beta-blockers have been performed to pro-
vide information on the mechanism of action. All studies
have shown that an improvement in left ventricular (LV)
ejection fraction (LVEF) can be obtained with beta-blocker
treatment. However, no randomized studies have been able
to demonstrate a significant antiremodeling effect of meto-
prolol on either LV dimensions or LV mass. The negative
or inconclusive findings in previous studies might have been
caused by inaccurate hemodynamic measurements since
they have all been performed with M-mode echocardiogra-
phy, two-dimensional echocardiography or LV angiogra-
phy. These methods are all associated with unsolved prob-
lems with methodology, observer-dependency and
precision, especially in a setting of patients with abnormally
shaped LVs. This study was performed as a substudy to the
MERIT-HF trial and was conducted with magnetic reso-
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nance imaging (MRI), which offers an unsurpassed preci-
sion in the measurement of heart volumes and function. The
aim was to investigate potential antiremodeling effects of
metoprolol CR/XL on the LV for patients with chronic
heart failure.
METHODS
Patients. In this study patients from the MERIT-HF
study were consecutively included in the period from Oc-
tober 1997 to April 1998. The inclusion took place at seven
Danish cardiology centers that participated in the
MERIT-HF trial, and all MRI examinations and other
measurements were performed at the Danish Research
Center of Magnetic Resonance at H:S Hvidovre Hospital.
The inclusion of patients in the study was terminated
concomitantly with the inclusion-termination in the
MERIT-HF trial in April 1998 (12).
The inclusion and exclusion criteria in this study were
identical to the criteria in the MERIT-HF trial, in which
the most important inclusion criteria were: patients with
symptoms of heart failure in NYHA functional classes II to
IV on optimal treatment for heart failure, LVEF #40% and
age between 40 and 80 years (18). Additional exclusion
criteria in this study with respect to the MRI examination
were atrial fibrillation, implanted pacemaker, implanted
mechanical heart valves, implanted insulin pump and claus-
trophobia.
Study design. The first MRI examination took place after
the inclusion in the MERIT-HF trial, but before the
randomization. At this point the patients had not yet
received the blinded study medication. The second exami-
nation took place five weeks after randomization if the
patients had received 25 mg of metoprolol CR/XL/placebo
as an initial dose of study medication or, alternatively, seven
weeks after randomization if the patients had received
12.5 mg of metoprolol CR/XL/placebo as an initial dose.
An initial dose of 25 mg metoprolol CR/XL/placebo per
day was recommended for patients in NYHA class II, and
an initial dose of 12.5 mg metoprolol CR/XL/placebo was
recommended for patients in NYHA classes III and IV. In
the MERIT-HF trial, the target dose of study medication
was 200 mg, and the recommended up-titration period was
six to eight weeks. Thus, the patients examined in this study
at five or seven weeks after randomization were on a daily
dose of 100 mg metoprolol CR/XL. The third examination
took place six months after randomization. At this point the
patients had been on the target dose of metoprolol CR/XL
for four months.
The study was approved by the Copenhagen Committee
on Scientific Ethics and, after written informed consent, a
total of 48 patients were included in the study. Of these, 41
patients were examined at all three examinations, and 7
patients were examined only once. The reasons for the
withdrawal of the seven patients who were examined only at
baseline before the metoprolol CR/XL/placebo treatment
were that one patient died (before the first dose of study
medication); three patients were withdrawn early from the
MERIT-HF trial because of suspected side effects (two
patients randomized to placebo and one patient randomized
to metoprolol CR/XL), and three patients were withdrawn
from this study because of claustrophobia (two patients
randomized to placebo and one patient randomized to
metoprolol CR/XL).
In order to obtain comparable measurements regarding
hormonal circadian rhythm, all examinations were per-
formed between 1 PM and 4 PM. At each examination, an
MRI study was performed, and heart rate was measured
continuously during the MRI-investigation and determined
as the average heart rate (HR) during the volume measure-
ment of the LV. Blood pressure was measured before the
MRI-examination after 20 min of rest in a sitting position.
In addition, body weight and height were measured, and
body surface area was calculated (19).
MRI investigation. The study was carried out on a whole-
body MR scanner (Siemens Impact Magnetom, Siemens,
Erlangen, Germany) operating at 1.0 tesla with a phased
array chest coil as receiver coil. Each slice of the LV was
obtained over 15 heartbeats with an electrocardiogram-
triggered breath-hold fast low-angle shot cinematographic
sequence in the true short axis plane with a temporal
resolution of 55 ms. Slice thickness was 10 mm; field of view
was 263 3 350 mm, and matrix size was 126 3 256. The
LV was encircled using a stack of 10 to 15 slices (20–22).
MRI postprocessing. The images were analyzed using the
computer program RGBwin developed at the Cardiovascu-
lar Magnetic Resonance Unit, Royal Brompton Hospital,
London, England. The MRI-examinations were all ana-
lyzed in one batch in a blinded manner, and the analysis was
completed before the treatment-code was broken in the
MERIT-HF trial. In each examination the number of slices
to include in the covering of the LV in end-diastole and
end-systole were decided, and, typically, one slice less in
end-systole than in end-diastole was included due to systolic
Abbreviations and Acronyms
CI 5 cardiac index
HR 5 heart rate
LV 5 left ventricle or ventricular
LVEDV 5 left ventricular end-diastolic volume
LVEDVI 5 left ventricular end-diastolic volume
index
LVEF 5 left ventricular ejection fraction
LVESV 5 left ventricular end-systolic volume
LVESVI 5 left ventricular end-systolic volume index
LVmassI 5 left ventricular mass index
LVSI 5 left ventricular stroke volume index
LVSV 5 left ventricular stroke volume
MERIT-HF 5 metoprolol CR/XL randomized
intervention trial in heart failure
MRI 5 magnetic resonance imaging
NYHA 5 New York Heart Association
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shortening of the LV. End-systole was chosen at the point
where the total LV blood pool was smallest. On each
end-diastolic frame, both inner and outer circumferences of
the LV myocardium were defined for volume and mass
determination. On each systolic frame, the inner circumfer-
ence of the myocardium was defined for volume determi-
nation. The papillary muscles were included as part of the
muscle mass and not as part of the chamber volume (23).
The borders marked for each of the three volumes over the
stack of contiguous slices were used to calculate the relevant
volumes by simple addition of the individual slice-volumes
since there were no interslice gaps.
In this manner the following volumes were determined:
LV end-diastolic volume (LVEDV), left ventricular end-
systolic volume (LVESV) and LVEDV at the outer circum-
ference of the myocardium. From these measurements the
following variables were calculated: LV mass (LVmass) was
determined as the difference between the LVEDV at the
inner and outer circumferences of the myocardium multi-
plied by a density-factor of 1.05 (21). Left ventricular stroke
volume (LVSV) was determined as the difference between
LVEDV and LVESV. Left ventricular ejection fraction was
determined as LVSV divided by LVEDV, cardiac output
was determined as LVSV multiplied by the heart rate.
Subsequently, all MRI variables, apart from LVEF, were
indexed by division with body surface area.
Variables for subsequent statistical analysis. For the sub-
sequent statistical analysis the following variables were
selected: LVEDV index (LVEDVI), LVESV index
(LVESVI), left ventricular stroke volume index (LVSI),
LVEF, cardiac index (CI), LVmass index (LVmassI), HR,
systolic blood pressure and diastolic blood pressure.
It was decided not to include the seven patients who were
examined only at baseline into the analysis, thus leaving 22
patients in the placebo group and 19 patients in the
metoprolol CR/XL group at all three examination points.
Statistics. Two-sample t tests between groups were per-
formed at baseline. Verification of normal distribution of
data was accomplished using histograms. The statistical
approach in the study was to fit a linear regression of each
subject’s data on time, which is often named “stochastic
regression analysis.” The slope of the lines (each represent-
ing one subject at all examination times) represented the
rate of change of the measurement per unit of time.
Subsequently, the mean slope of each of the two treatment
groups (calculated as the mean value of all slopes in each
group) was tested against 0, and the mean slopes of the two
treatment groups were tested against each other using t
tests. Thus, analysis of all data from the repeated measure-
ments was performed in one step. Before the stochastic
regression analysis, data were evaluated on scatter plots for
linearity control. After the stochastic regression analysis
procedure, a model control consisting of residual column
plots, standardized residuals versus predicted value plots and
normal plots was applied, which showed that all conditions
for the statistical procedure had been fulfilled. All data fit a
normal distribution model, and no transformation of data
has been made. Data from all three examinations were
included in the analysis. In all tests a significance level of 5%
has been used. All tests were performed in the SAS system
(SAS Institute Inc., Cary, North Carolina).
RESULTS
The entry characteristics of the patients in this study
compared with the entry characteristics in the MERIT-HF
trial are given in Table 1. No major differences between
patients in this study and patients in the MERIT-HF trial
were found. The results of this study are summarized in
Table 2 and Figures 1 to 4. For all variables, no differences
were found between the two groups at baseline. During the
study period, LVEDVI and LVESVI decreased, and LVEF
increased significantly in the metoprolol CR/XL group
versus baseline and versus placebo. No changes were seen in
the placebo group with regard to these variables. At five or
seven weeks after the baseline examination, an average
decrease in LVEDVI of 7%, an average decrease in
LVESVI of 10% and an average increase in LVEF of 10%
were found. The data at six months after baseline revealed a
similar, but more marked, decrease in LVEDVI and
LVESVI of 16% and 24%, respectively, as well as an average
increase in LVEF of 28% (Fig. 1 to 3). No change was seen
in LVSI, but a significant decrease in CI versus baseline of
18% at six months after baseline was found in the meto-
prolol CR/XL group. A significant decrease in HR of 24%
after six months of treatment was found in the metoprolol
CR/XL group. For LVEDVI, LVESVI, LVEF, LVSI, CI
and HR, no significant changes were seen in the placebo
group. Left ventricular mass index decreased significantly
and uniformly in the two groups versus baseline (9% and 8%
in the placebo and metoprolol groups, respectively, after six
months), and no significant difference was found between
the groups (Fig. 4). A significant decrease in systolic blood
pressure was found in the placebo group versus baseline,
Table 1. Baseline Characteristics in this Study and in the
MERIT-HF Trial
MRI Substudy
(n 5 41)
MERIT-HF
(n 5 3,991)
Mean age (yrs) 66 64
Male gender (%) 85 77
NYHA classification (%)
II 51 41
III 46 55
IV 3 4
Heart rate (beats/min) 81 82
BP (diastolic) (mm Hg) 76 78
BP (systolic) (mm Hg) 132 129
Mean LVEF (%) 27 28
BP 5 blood pressure; LVEF 5 left ventricular ejection fraction; MERIT-HF 5
metoprolol CR/XL randomized intervention trial in heart failure; MRI 5 magnetic
resonance imaging; NYHA 5 New York Heart Association functional class. All
classifications and measurements were derived from the baseline examination in the
MERIT-HF trial (12, 18).
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whereas no change was seen in the metoprolol CR/XL
group. A significant decrease in diastolic blood pressure was
found in the metoprolol CR/XL group versus baseline,
while no change was seen in the placebo group. Body
surface area was unchanged in both groups.
DISCUSSION
Main findings. In this study we found a significant reduc-
tion in LVEDVI and LVESVI as well as a significant
increase in LVEF after six months of treatment with
metoprolol CR/XL. The net effect was an unaltered LVSI
Table 2. Results
Group
Pla: n 5 22
Meto: n 5 19
Baseline
Mean Values
(95% CI)
5/7 Weeks
Mean Values
(95% CI)
6 Months
Mean Values
(95% CI)
p Value
t Test:
Difference
Between
Groups
at Baseline
Effect
Over
Time
p Value
t Test:
Change Over
Time Within
Each Group
p Value
t Test:
Difference
Between
Groups
Over Time
LVEDVI
(ml/m2)
Pla
156 153 158
3 NS
(123, 189) (119, 186) (122, 194)
NS 0.01
Meto
150 140 126
2 0.007
(128, 172) (121, 160) (114, 138)
LVESVI
(ml/m2)
Pla
111 110 113
3 NS
(80.2, 141) (77.4, 142) (78.6, 147)
NS 0.001
Meto
107 97.3 80.6
2 0.001
(88.6, 126) (79.8, 115) (70.2, 90.9)
LVSI (ml/m2)
Pla
43.4 42.8 44.9
3 NS
(37.6, 53.2) (35.7, 49.8) (37.9, 51.9)
NS NS
Meto
42.5 42.9 45.6
3 NS
(35.6, 49.4) (38.5, 47.3) (40.5, 50.8)
LVEF (%)
Pla
32.0 33.0 33.0
3 NS
(27.0, 38.0) (27.0, 39.0) (28.0, 39.0)
NS 0.03
Meto
29.0 32.1 37.0
1 0.005
(25.0, 34.0) (28.1, 36.2) (33.0, 41.0)
CI (l/min/m2)
Pla
3.28 3.22 3.29
3 NS
(2.90, 3.88) (2.70, 3.74) (2.74, 3.84)
NS NS
Meto
3.36 2.82 2.77
2 0.03
(2.80, 3.91) (2.46, 3.18) (2.50, 3.04)
LVmassI (g/m2)
Pla
175 169 160
2 0.005
(154, 197) (145, 194) (136, 184)
NS NS
Meto
179 173 164
2 0.01
(156, 203) (152, 194) (148, 180)
Heart rate
(beats/min)
Pla
76.4 76.2 73.6
3 NS
(71.3, 81.5) (70.5, 81.9) (67.2, 80.0)
NS 0.0005
Meto
81.7 66.4 61.8
2 6 3 1026
(74.7, 88.8) (59.7, 73.7) (57.1, 66.6)
BP (diastolic)
(mm Hg)
Pla
75.5 73.3 72.8
3 NS
(70.1, 80.9) (69.0, 77.7) (67.9, 77.7)
NS NS
Meto
79.1 73.3 72.3
2 0.02
(74.5, 83.7) (68.3, 78.2) (66.0, 78.5)
BP (systolic)
(mm Hg)
Pla
140 126 123
2 0.02
(127, 154) (116, 137) (114, 131)
NS NS
Meto
134 126 131
3 NS
(123, 145) (115, 137) (118, 144)
BSA (m2)
Pla
1.51 1.51 1.52
3 NS
(1.43, 1.59) (1.43, 1.59) (1.44, 1.59)
NS NS
Meto
1.48 1.48 1.50
3 NS
(1.41, 1.56) (1.41, 1.56) (1.41, 1.58)
Age (years)
Pla
66.5
- - - -
(63.2, 69.8)
NS -
Meto
65.4
- - - -
(60.9, 69.9)
Gender (% male)
Pla 81.8 - -
NS
- -
-
Meto 84.2 - - - -
3 5 no effect over time; 2 5 a decrease over time; 1 5 an increase over time; 95% CI 5 95% confidence interval; BP 5 blood pressure; BSA 5 body surface area; CI 5
cardiac index; effect over time 5 direction of trend over time of the variables within the group; LVEDVI 5 left ventricular end-diastolic volume index; LVEF 5 left ventricular
ejection fraction; LVESVI 5 left ventricular end-systolic volume index; LVmassI 5 left ventricular mass index; LVSI 5 left ventricular stroke volume index; Meto 5 metoprolol
CR/XL group; NYHA 5 New York Heart Association functional class; Pla 5 placebo group. Mean values are given for examinations at baseline, at 5/7 weeks and six months
after randomization.
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with the LV at a better hemodynamic set point on the
Frank-Starling curve than before the metoprolol CR/XL
treatment. This is the first randomized study to demonstrate
this very important antiremodeling effect of metoprolol in
the treatment of chronic heart failure, which might be one
of the key explanations for the highly significant 49%
Figure 1. LVEDVI over time. Mean LVEDVI is shown in the metoprolol CR/XL group and in the placebo group at baseline, five or seven weeks and
six months after randomization. *The metoprolol CR/XL group versus the placebo group. CI 5 confidence interval; LVEDVI 5 left ventricular
end-diastolic volume index.
Figure 2. LVESVI over time. Mean LVESVI is shown in the metoprolol CR/XL group and in the placebo group at baseline, five or seven weeks and six
months after randomization. *The metoprolol CR/XL group versus the placebo group. CI 5 confidence interval; LVESVI 5 left ventricular end-systolic
volume index.
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reduction in the total number of deaths from worsening
heart failure found in the MERIT-HF trial (12). Previous
hemodynamic metoprolol studies have found significant
improvements in LVEF after the active treatment, but no
randomized study has been able to detect any significant
antiremodeling effect (7,24–32).
In addition to the MERIT-HF trial, several large mor-
tality trials with other beta-receptor antagonists of patients
Figure 3. LVEF over time. Mean LVEF is shown in the metoprolol CR/XL group and in the placebo group at baseline, 5 or 7 weeks and six months after
randomization. *The metoprolol CR/XL group versus the placebo group. CI 5 confidence interval; LVEF 5 left ventricular ejection fraction.
Figure 4. LVmassI over time. Mean LVmassI is shown in the metoprolol CR/XL group and in the placebo group at baseline, five or seven weeks and six
months after randomization. *The metoprolol CR/XL group versus the placebo group. Metoprolol CR/XL group versus baseline: p 5 0.01; placebo group
versus baseline: p 5 0.005. CI 5 confidence interval; LVmassI 5 left ventricular mass index.
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with chronic heart failure have recently been performed.
Two trials have been conducted with the combined
alpha1beta1&2-receptor antagonist, carvedilol, in which de-
creases in mortality of 65% after 12 months of treatment
(13) and 21% after 19 months of treatment (10) were found.
Furthermore, one trial has been carried out with the
beta1-selective receptor antagonist with no intrinsic activity,
bisoprolol, in which a reduction in mortality of 32% after 16
months of treatment was found (11).
The exact mechanism behind the mortality reduction in
chronic heart failure after beta-blocker treatment is not yet
fully elucidated but is expected to arise from a combination
of an antiarrhythmic effect and an improvement in the
hemodynamic function of the LV caused by a combination
of HR reduction and inhibition of the detrimental neuro-
hormonal activation virtually always present in patients with
chronic heart failure (17). The two carvedilol studies have
not attempted to stratify the reduction in mortality with
regard to these causes. In the bisoprolol trial a significant
decrease in mortality from sudden death of 42% and an
insignificant reduction in mortality from worsening heart
failure were demonstrated after stratification of total mor-
tality. Thus, the MERIT-HF trial is the only beta-blocker
mortality trial to have confirmed a significant benefit on
mortality from hemodynamic causes. No clinical studies on
the effects of bisoprolol on LV dimensions or function have
been published, but several carvedilol studies have been
published in which hemodynamic effects comparable with
the findings in the present metoprolol study have been
demonstrated (30,33–36). The view that metoprolol and
carvedilol seem to exert similar effects on LV dimensions
and function is supported by results from two comparative
studies on the hemodynamic effects of metoprolol and
carvedilol in patients with chronic heart failure, in which no
significant hemodynamic differences were found between
the two agents (30,34).
Cardiac index. As a natural consequence of a stable LVSI
and a marked decrease in HR found in this study and by all
previous investigators, a significant decrease in CI versus
baseline was seen after metoprolol CR/XL treatment. Pre-
vious studies have found insignificant effects on (7,24,28,34)
or small increases in (29,32,37) CI at rest. From a clinical
point of view, this hemodynamic variable is more interesting
in an exercise situation than in a resting state. We have not
addressed this issue in our study, but others have found
beneficial hemodynamic exercise effects of metoprolol, in-
dicating that the improvement in LV function in an exercise
situation overrides the decrease in maximum HR
(7,25,29,31,37,38).
LV mass. We found significant decreases in LV mass in
both the placebo group and the metoprolol CR/XL group
without any difference between the groups. Previously, one
randomized study found no effect on LV mass after three
months of metoprolol treatment, whereas, in an uncon-
trolled 18-month continuation of the same trial, a signifi-
cant 18% decrease in LV mass was found (27). A possible
explanation for the reduction in LV mass in both groups in
this study might be found in the design of the MERIT-HF
trial with its run-in period immediately preceding the
randomization in which the patients were optimized in
conventional heart failure treatment (18). This treatment-
optimization of both groups, in which the patients typically
had an angiotensin-converting enzyme inhibitor added or
adjusted or had their diuretic medication attuned, might
explain the improvement in both groups in this study. We
found no evidence that the metoprolol CR/XL treatment in
itself had any impact on this variable. However, in the
metoprolol CR/XL group, the concomitant decrease in LV
size and mass suggests that wall thickness remained about
the same, and, because systolic blood pressure did not
change, average systolic wall stress may consequently have
decreased during the study period. Although we do not have
wall stress data, this possible effect may constitute another
beneficial effect of metoprolol CR/XL for patients with
chronic heart failure.
Investigation method. This study was performed as an
MRI study and differs, as such, from previously published
beta-blocker heart failure studies. Compared with conven-
tional methods such as M-mode echocardiography, two-
dimensional echocardiography and LV angiography, MRI
offers several advantages since no geometrical assumptions
are applied in the determination of LV volumes and mass
(39). This is mainly of importance for patients with an
abnormally shaped LV, as is frequently the case for patients
with chronic heart failure. Furthermore, MRI is totally
independent of lung cover and disposition of the heart (40)
and finally, MRI offers a reproducibility in the determina-
tion of all LV volumes of 2% to 5%, which is markedly
lower than that offered by other methods (40–42). This
considerably reduces the number of patients required to
detect intergroup differences in LV dimensions and func-
tion and may explain why this study is the first to demon-
strate a significant antiremodeling effect from metoprolol in
chronic heart failure.
Drug safety. With regard to hemodynamic parameters,
metoprolol CR/XL seemed to be a hemodynamically safe
drug in the treatment of chronic heart failure. Even though
one patient died and three patients were withdrawn because
of suspected side effects from the metoprolol CR/XL/
placebo treatment, their withdrawal from this study had no
impact on the conclusions since these patients were equally
distributed in the placebo and metoprolol CR/XL groups.
Furthermore, it is evident from the data at the second
examination at five to seven weeks after randomization that
LV function did not deteriorate at this point during the
run-in period of metoprolol CR/XL. In other studies
performed with short acting metoprolol, a potential de-
crease in LVEF during the very early phase of beta-blocker
up-titration has been reported (43,44). In this study a slow
release compound of metoprolol was up-titrated very cau-
tiously over a protracted period, which might have been a
2078 Groenning et al. JACC Vol. 36, No. 7, 2000
Antiremodeling Effects of Beta-Blockade December 2000:2072–80
critical factor for the positive outcomes of this study and the
MERIT-HF trial (18).
Conclusions. This substudy to the MERIT-HF trial is the
first randomized study to demonstrate that the beta1-
blocker metoprolol CR/XL has antiremodeling effects on
LV dimensions and function in patients with chronic heart
failure and consequently provides an explanation for the
highly significant decrease in mortality from worsening
heart failure found in the MERIT-HF trial.
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